参考文献

1.Mountzios G，Dimopoulos MA，Soria JC，et al. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer：a review of published data. Crit Rev Oncol Hematol，2010，75：94-109.

2.Sheth S. Current and emerging therapies for patients with advanced non-small-cell lung cancer.Am J Health Syst Pharm，2010，67（Suppl 1）：S9-S14.

3.Kim SJ，Rabbani ZN，Dong F，et al. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Med Oncol，2010，27：91-97.

4.Toffalorio F，Giovannetti E，De Pas T，et al. Expression of gemcitabine-and cisplatin-related genes in non-smallcell lung cancer. Pharmacogenomics J，2010，10：180-190.

5.Cetin Z，Ozbilim G，Erdogan A，et al. Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. Med Oncol，2010，27：853-860.

6.Kalikaki A，Koutsopoulos A，Hatzidaki D，et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.Lung Cancer，2010，69：110-115.

7.Lee YJ，Cho BC，Jee SH，et al. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol，2010，28：487-492.

8.Adams VR，Harvey RD. Histological and genetic markers for non-small-cell lung cancer：customizing treatment based on individual tumor biology. Am J Health Syst Pharm，2010，67（1 Suppl 1）：S3-S9.

9.Yoshioka H，Hotta K，Kiura K，et al. A phase Ⅱ trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations：Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol，2010，5：99-104.

10.Douillard JY，Shepherd FA，Hirsh V，et al. Molecular predictors of outcome with gefi tinib and docetaxel in previously treated non-small-cell lung cancer：data from the randomized phase ⅢINTEREST trial. J Clin Oncol，2010，28：744-752.

11.Yoshida K，Yatabe Y，Park J，et al. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. J Cancer Res Clin Oncol，2010，136：527-535.

12.Mathieu A，Weynand B，Verbeken E，et al. Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer. Lung Cancer，2010，69：46-50.

13.Jeong SH，Jung JH，Han JH，et al. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.Lung Cancer，2010，68：288-294.

14.Wang X，Zhao J，Yang L，et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol，2010，27：484-490.

15.Lee JJ，Maeng CH，Baek SK，et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1（RRM1）protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer（NSCLC）. Lung Cancer，2010，70：205-210.

16.Dong S，Guo AL，Chen ZH，et al. RRM1 single nucleotide polymorphism -37CA correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J Hematol Oncol，2010，3：10.

17.Suda K，Tomizawa K，Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer：an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev，2010，29：49-60.

18.Mao C，Qiu LX，Liao RY，et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer：a meta-analysis of 22 studies. Lung Cancer，2010，69：272-278.

19.Sasaki T，Rodig SJ，Chirieac LR，et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer，2010，46：1773-1780.